Cost and affordability of scaling up tuberculosis diagnosis using Xpert MTB/RIF testing in West Java, Indonesia

Mardiati Nadjib1*, Retno Kusuma Dewi2, Ery Setiawan3, Tri Yunis Miko4, Septiara Putri1, Panji Fortuna Hadisoemarto5, Euis Ratna Sari6, Pujiyanto1, Rani Martina6, Lusi Nursilawati Syamsi7

1 Department of Health Policy and Administration, Faculty of Public Health Universitas Indonesia, Depok, Indonesia, 2 National TB Program, Ministry of Health Republic of Indonesia, Jakarta, Indonesia, 3 Center for Health Economics and Policy Studies, Universitas Indonesia, Depok, Indonesia, 4 Department of Epidemiology, Faculty of Public Health Universitas Indonesia, Depok, Indonesia, 5 Department of Public Health/Tuberculosis Working Group, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia, 6 District Health Office, Depok Municipality, West Java, Indonesia, 7 Department of Internal Medicine, Sentra Medika Hospital, Depok, Indonesia

* mardiatinadjib@gmail.com

Abstract

In Indonesia, a significant number of tuberculosis (TB) cases may be missed, due to the low sensitivity and specificity of the currently used diagnostic algorithm. In this regard, the rapid molecular test using Xpert MTB/RIF, which has recently been introduced in Indonesia, can improve case detection. Thus, this study determined the cost and affordability of incorporating Xpert MTB/RIF testing for TB diagnosis. For this purpose, we estimated the costs (from the health system and societal perspectives) of reaching the TB detection target in Depok municipality, and applied the findings to the West Java province of Indonesia. The resources available for the health and TB program were also analyzed to support the decision to scale up the TB diagnosis using Xpert MTB/RIF testing. According to the results, the unit cost for TB diagnosis per person was USD 27.22 and USD 70.16 from the health system and societal perspectives, respectively. To reach the target of 109,843 TB cases for the 2020–2024 time period, Depok municipality would need USD 2,989,927 and USD 2,549,455 from the health system viewpoint, assuming the machine’s lifespan of five and 10 years, respectively. Extrapolating these results to the West Java province, USD 56,353,833 would be necessary to test 2,076,413 cases from 2019 to 2024. However, in order to accelerate the case detection target up to 2024, West Java requires additional funds. The implication of the findings is that the central government must consider local capacity to accelerate TB case detection and ensure that the installation of Xpert MTB/RIF machines is included in the overall costs.
Introduction

Background

Although Indonesia has experienced noticeable progress in tuberculosis (TB) control over the last decade, TB remains one of the top four causes of death in the country [1]. For example, the estimated TB incidence among Indonesian adults (15 years old and above) in 2018 was 316 (95% CI: 288–345) per 100,000 population, which corresponds to a projected number of 845,000 (95% CI: 770,000–923,000) TB cases per year [2]. Additionally, only 570,289 cases were identified, whereas the rest was undetected or unreported [2].

TB incidence in Indonesia incurred a cost of USD 6.9 billion to the national economy, which may be owing to undetected and untreated cases [3]. Specifically, the two highest liabilities were derived from the loss of productivity due to premature death and illness, comprising USD 6.0 billion and USD 700 million, respectively [3]. Besides the need to address various factors associated with the TB problem, an urgent need has emerged for strategies that increase the detection rate for TB cases. In this regard, Indonesia aimed to reduce TB incidence to 190 per 100,000 adults by 2024, as explicitly articulated in its National Strategic Plan [4].

The World Health Organization (WHO) recommends the use of Xpert MTB/RIF (Mycobacterium tuberculosis [MTB] complex and resistance to rifampin [RIF]) testing instead of conventional microscopy and culture [5–7]. Given the wide coverage of health centers in Indonesia, optimizing the detection of TB cases using more sensitive and specific diagnostic tools is important. The National TB Program (NTP) in Indonesia integrates this recommendation for detecting TB cases in primary care. Through the Ministry of Health’s (MOH) Regulation No. 67/2016 regarding TB control, the Indonesian government stipulates that its laboratory network use Xpert MTB/RIF testing for the diagnosis of drug-sensitive TB, drug-resistant TB (DR-TB), and TB in people living with HIV/AIDS [8]. The currently used diagnostic algorithm is based on bacteriological examination by sputum smear microscopy (SSM) using the Ziehl–Neelsen direct light technique followed by clinical examination with or without chest radiography (CXR) [8].

Although molecular diagnostic tools for TB and DR-TB are available in 878 health facilities in 478 districts [4], the MOH has been planning to increase the number of Xpert MTB/RIF testing units in the country [9]. In this regard, various studies have addressed the issue of the cost-effectiveness of Xpert MTB/RIF testing as an important approach for decision-making in low- and middle-income countries [10–14]. However, little is known about whether this type of diagnostic test is affordable, especially at the sub-national level. Thus, a budget impact analysis is important because it can provide information on the financial consequences of scaling up the use of Xpert MTB/RIF testing in the country [15]. Based on this objective, this study assesses the cost and affordability of using Xpert MTB/RIF testing to diagnose TB in 27 districts of West Java province.

Objective

The objective of this study is three-fold, namely, to (1) conduct a cost analysis of scaling up TB diagnosis using Xpert MTB/RIF testing; (2) estimate the budget impact for TB diagnosis during 2020–2024; and (3) determine the affordability of scaling up TB diagnosis using Xpert MTB/RIF testing in West Java province.

Materials and methods

Study setting

The study selected West Java (a high-burden province) as the study site, which had 156,143 incidences of TB in 2017 or 330 per 100,000 people (estimated case detection rate: 55%) [16].
This study was conducted in Bogor district, Cimahi municipality, and Depok municipality. The Bogor district had the highest number of notified TB patients among all of the districts in Indonesia, with 7,738 patients in 2014 and 10,405 cases in 2017, while Depok and Cimahi municipalities reported 3,734 and 1,802 TB cases, respectively [16].

Costing study

In this study, the cost data was captured from the societal perspective. The health system costs were completed in 2018, whereas data for patient costs were collected in 2019. All of the costs were converted into USD in 2018 and 2019, at the rate of 13,850 rupiah and 14,000 rupiah, respectively. No discounting or inflation rate adjustment was applied. We also used the cost data to simulate the budget impact for West Java covering 27 districts, based on purchasing power parity (PPP) and the data published by the Central Bureau of Statistics [17].

Real world costing studies were carried out in 13 purposively selected health centers and one tertiary hospital across three districts (Bogor district, Depok municipality, and Cimahi municipality). Specifically, 10 health centers in Bogor district were selected to represent the provision of TB diagnosis in this high burden district using SSM and SSM plus CXR, while three health centers in neighboring high burden districts (Bogor district and Depok municipality) represented the provision of TB diagnosis using Xpert MTB/RIF testing [18]. We also selected the providers based on specific criteria: availability of qualified staff/physicians, accessibility, and the government priority area for West Java province. As for the data, it was gathered to represent the patient flow from the registration desk to the end point where the patients received their TB diagnosis. This estimation considered all possible modalities for TB diagnosis in the current algorithm [8]. Moreover, we included the hospital as part of our costing study to capture the costs of providing Xpert MTB/RIF testing for the cases in which there was no access/availability to such testing at the health center.

Additional data was collected from one health center and one hospital in Depok to obtain comprehensive direct medical costs, direct non-medical costs, and indirect medical costs, as suggested by the WHO’s guideline [19]. These facilities represent various characteristics in terms of costs (infrastructure) and demographic issues (urban/rural). We analyzed the costing data from both the district and province levels, and extrapolated such data to represent the budget consequence of providing Xpert MTB/RIF testing in Depok and West Java province.

Data on patient costs were collected using a questionnaire that measured direct medical costs, direct non-medical costs, and indirect costs (foregone earnings) [19]. Direct medical costs included costs for consultation, administration, laboratory testing, CXR examination, and expenses during inpatient care related to diagnostic testing at the hospital. Alternatively, non-medical costs comprised costs incurred on food, travel, and caregiver/guardian. Notably, the income losses of patients were calculated as part of indirect costs [19, 20].

The patient costs data were collected from one health center and one private hospital in Depok, the only facilities assigned to provide Xpert MTB/RIF testing in the city. We captured the patient’s experience in receiving the diagnostic TB tests, starting from their search for care based on initial symptoms to being referred to the final diagnosis using Xpert MTB/RIF testing. Specifically, we employed a non-probability sampling method by consecutively enrolling pulmonary TB cases from July to August 2019, and assumed that the data from 31 patients in the health center and 31 patients in the hospital would be sufficient for capturing their expenses.

The inclusion criterion comprised patients aged ≥15 years who were referred from other health care centers/clinics to the two designated facilities in order to conduct a TB diagnosis using Xpert MTB/RIF testing. Any patients from vulnerable groups (e.g., pregnant women,
children, the elderly with comorbidities, etc.) or those who were unwilling to be interviewed were excluded from this study. Prior to the interviews, informed consent was obtained by each participant and his/her representative, while for the participants under the age of 18, parental consent was documented.

The health system costs were defined as the sum of all direct and indirect healthcare costs, including incidental one-off costs (e.g., purchasing an Xpert MTB/RIF machine) as well as maintenance and routine costs (e.g., operational costs, consumables, staff costs, and other operational costs). The consumables cost was considered as a variable cost measured per each diagnosis procedure. We also estimated the annual value of equipment cost and then divided it by the total annual utilization for certain activities such as total SSM, CXR, and Xpert MTB/RIF testing. Over a 3-year period, the costs for the Xpert MTB/RIF machine, cartridge, and maintenance were USD 17,000, 10, and 7,902, respectively, per machine [21]. In addition, we estimated the number of annual tests per day based on the MOH’s suggestion regarding the capacity and utilization of the machine. In this regard, less than 10 tests per day were considered as low, 10–50 tests per day were considered as moderate, and more than 50 tests per day were considered as high. We assumed that the Xpert MTB/RIF machine would perform three modules per day or 12 expected tests per day. Based on the findings, in Depok, the number of Xpert MTB/RIF tests was 1,925 per year or approximately eight tests per day. For the analysis, we assumed that the health centers could perform roughly 2880–3000 tests annually, according to 20–21 working days per month.

Finally, the unit of analysis was presented as per patient value. Hence, the unit cost represented the amount of money spent by each household for one diagnostic procedure, including both health system and patient costs. Moreover, the cost per case was derived from the cost analysis and the number of cases detected for each of the current modalities, while the total annual cost of using Xpert MTB/RIF testing was calculated by multiplying the unit cost by the number of tests required per year for the target population. We also calculated the costs for SSM to determine the financial consequences of scaling up the TB diagnosis using Xpert MTB/RIF testing.

**Number of TB diagnostic tests needed and affordability**

The data from the Depok municipality regarding the number of TB presumptive cases as well as the number of SSM and Xpert MTB/RIF tests for the 2016–2018 time period were extracted from the national electronic TB register. The number of Xpert MTB/RIF tests in the study area partly contributed by transporting the specimens from other health centers. Since this approach has not been launched as a national program, for this study, we focused on capturing on-site Xpert MTB/RIF testing (out-patient visits) and expecting more health centers to provide such testing in West Java.

A budget impact analysis for the 2019–2024 time period was conducted based on the cost data collected and the number of cases detected by the West Java Provincial Health Office (PHO). Conceptually, affordability was assessed by comparing the costs of Xpert MTB/RIF testing relative to currently available funds [6]. To determine the affordability of the proposed budget, this study compared the cost of the targeted Xpert MTB/RIF testing relative to total health expenditures (specifically on TB care and control). Information was derived from the District Health Office (DHO) and the Local Government Medium-Term Development Plan for 2018–2023 [22]. In summary, the data sources comprised primary data and official documents (Table 1).

**Budget impact scenario and uncertainty**

We estimated the cost of providing Xpert MTB/RIF testing in Depok and West Java by multiplying the unit cost and number of targeted cases. Based on the findings, the proportions of the cases using SSM and Xpert MTB/RIF testing included: 60% by SSM and 40% by Xpert
MTB/RIF (60:40) in 2019, 50:50 in 2020, 45:55 in 2022, and 40:60 in 2024 [23]. In addition, a budget impact scenario was undertaken deterministically regarding the expected years of useful life for a Xpert MTB/RIF machine at 10 years, instead of five years. We also assessed the uncertainty of certain parameters incurred in cost calculations, including: costs, number of TB cases, and total costs (scenario).

**Ethics**

This study was approved by the Research and Community Engagement Ethical Committee in the Faculty of Public Health at Universitas Indonesia (Approval No. 555/UN2.F10/PPM.00.02/2019).

**Results**

**Unit cost of TB diagnostic tests in Depok**

The average costs of the laboratory tests provided by the health center and hospital were USD 2.02 per test for the SSM, USD 8.86 for the CXR, and USD 27.22 for the Xpert MTB/RIF, including maintenance costs (see Table 2). The costs also included the annual cost of the staff performing such tests. Based on the findings, the Xpert MTB/RIF machine, cartridge, and maintenance costs were the three largest cost components for Xpert MTB/RIF testing, which are currently subsidized by the central government.

The average patient cost (the health center and hospital) was USD 3.79 for the SSM, USD 22.19 for the CXR, and USD 42.94 for the Xpert MTB/RIF. As for the indirect costs (foregone earnings), they accounted for 32% to 58% of the total patient costs. It should be noted that the majority of the patients were covered by social insurance schemes. Thus, the direct medical

---

Table 1. Methods used to estimate the number of TB tests and costs in Depok municipality and West Java province.

| Variable | Description | Source |
|----------|-------------|--------|
| Presumptive TB cases | All people with TB signs and symptoms | DHO Depok and PHO West Java |
| • SSM | Suspected TB with SSM test if negative, followed by a chest x-ray (CXR) | DHO Depok and PHO West Java |
| • Xpert MTB/RIF | Presumptive TB using Xpert MTB/RIF testing | DHO Depok and PHO West Java |
| Estimated number of TB cases | Estimated number of cases in 2016–2019 (existing) and 2020–2024 | DHO Depok and PHO West Java |
| Case projection based on the scenario | Coverage of TB cases with SSM tests | DHO Depok and PHO West Java |
| • Case with symptoms and SSM test | Coverage of TB cases with Xpert MTB/RIF testing | DHO Depok and PHO West Java |
| Cost of diagnosis | Cost of TB diagnosis in the health center or hospital for SSM and Xpert MTB/RIF testing | Primary data |
| • Health system perspective | Cost of healthcare component related to TB diagnosis | Primary data |
| • Patient perspective | Patient costs, including transportation and other direct non-medical costs | Primary data |
| • Societal perspective | Direct medical, direct non-medical, and indirect costs for TB diagnostic tests | Primary data |
| Budget impact | Resource needed for Xpert MTB/RIF testing for the period 2020–2024 | Estimate for the period 2020–2024 is based on costs (health system and patient costs) and TB case projection for West Java |
| Financing (affordability) | Resource available for the TB program/affordability | District Health Account Depok; West Java Province Medium-term Development Plan; and public funding documents |
| • Public funding | Government financial support for the TB program and the health sector at the sub-national level | Primary data |

https://doi.org/10.1371/journal.pone.0264912.t001
costs paid out-of-pocket (in most cases) were relatively low. However, such costs were higher for those who were treated at the hospital and required inpatient care. Regarding the direct non-medical costs for transportation, meals, and caregiver/guardian, they were relatively lower than the other components, although the costs (especially transportation) were considered as the main challenge for accessing care among the patients from both rural and urban areas [20]. Moreover, a statistical analysis revealed that the type of facility and transportation was associated with a higher average cost (see Table 3).

The number of positive bacteriological cases using SSM in 2016 was 1,372, while using CXR on negative bacteriological cases with positive clinical symptoms resulted in an additional 1,451 clinical TB cases. From the health system perspective, the costs incurred by Depok in 2016 were USD 15,528 for SSM and USD 83,635 for SSM-CXR. From the societal perspective, the costs were USD 22,677 and USD 151,818, respectively. The largest cost components for the SSM, CXR, and Xpert MTB/RIF were direct medical costs, each of which contributed 69%, 59%, and 68% of the total costs, respectively. This was followed by transportation costs that (on average) contributed 30% of the total costs. The findings for the Xpert MTB/RIF testing gave a 26.7% positivity rate, with 870 resistant cases in 2018, out of the 3,400 cases. The number of resistant cases that were later referred to hospitals were 32 in 2017 and 65 in 2018. Regarding the costs from the health system and societal perspectives, and the cost per case detected using Xpert MTB/RIF testing in the 2016–2018 time period, see Table 4.

### Budget impact for TB tests in Depok, 2019–2024

The case detection target for Depok was established by the PHO, increasing from 6,268 in 2019 to 6,601 in 2024 (see Table 5). Thus, we applied this increase in Xpert MTB/RIF testing from 2019 to 2024. This table also shows the number of cases using such testing and its costs. Specifically, in 2019, the total cost was USD 409,554 and USD 584,816, from the health system and societal perspectives, respectively. However, it is expected to increase to USD 610,955 for the health system perspective and USD 871,235 for the societal perspective by 2024. The historical data from the study area also showed a positivity rate of 26.7% for Xpert MTB/RIF testing and 10% for SSM, effectively yielding positivity values of 3,615 in 2019 and 5,710 in 2024.

During this study, there were only two machines. However, in order to achieve the target set up by the PHO, six devices were required. Additionally, to reach the target of 109,843 TB cases detected using Xpert MTB/RIF testing in the 2019–2024 time period, Depok would need

### Table 2. Average cost per person tested (USD).

| Cost perspective                  | Polyclinic | CXR     | SSM     | Xpert MTB/RIF |
|----------------------------------|------------|---------|---------|---------------|
| Health system                    | 1.90       | 8.86    | 2.02    | 27.22         |
| Direct non-medical               | -          | 6.04    | 0.93    | 11.55         |
| Indirect                         | -          | 16.14   | 2.86    | 31.39         |
| Total                            | -          | 22.19   | 3.79    | 42.94         |
| Societal (95% CI)                | 1.90       | 14.90   | 2.95    | 38.77         |
| Lab only + direct non-medical    | -          | 22.19   | 3.79    | 42.94         |
| Societal (95% CI)                | 1.90       | 31.04   | 5.81    | 70.16         |
| Lab only + direct non-medical + indirect | -          | 22.19   | 3.79    | 42.94         |

https://doi.org/10.1371/journal.pone.0264912.t002
USD 2,989,927 and USD 2,549,455, assuming the useful life of the machine is five years and 10 years, respectively. According to the National Strategic Plan, by 2024, 75% of the tests will use Xpert MTB/RIF testing. Hence, for 2024 only, Depok would require USD 727,701 and USD 620,497, with the useful life of the machine at five years and 10 years, respectively [4].

Affordability in Depok

Based on the findings, spending on TB programs in Depok generally increased, with the majority of the funds dedicated to monitoring drug compliance and supporting outreach programs. The TB tests, especially those using Xpert MTB/RIF testing, were highly subsidized by the central government, including support from the Global Fund [24]. However, the Global Fund support will end in 2023, after which it will become a challenge to continue these efforts without the government replacing such support (as an exit strategy), even for a region with high fiscal capacity such as Depok.

Table 6 shows that out of approximately USD 30 million in support for the health sector in Depok per year, spending on the TB program was relatively low, i.e., USD 77,326 and USD 128,929 in 2017 and 2018, respectively. This is an interesting finding, considering that TB is a priority public health issue in Depok.

Budget impact analysis of the TB diagnosis program in West Java

West Java includes 27 districts/cities with high to very high fiscal capacities, and two with low regional fiscal capacities [25]. Hence, a budget impact analysis for West Java for the next five years would be useful to assess the financial implications of scaling up tuberculosis diagnosis using Xpert MTB/RIF testing.

Table 3. Cost variations by patients’ socio-demographic variables.

| Category                | N (%) | Mean in USD (SD) | p-value |
|-------------------------|-------|------------------|---------|
| Age ***                 |       |                  |         |
| ≤20                     | 4 (6%) | 42.20 (6.35)     | 0.0517  |
| 21–40                   | 31 (50%) | 41.36 (13.08)   |         |
| 41–60                   | 19 (31%) | 52.16 (16.60)   |         |
| ≥61                     | 8 (13%) | 41.15 (12.18)    |         |
| Type of health facility * |      |                  |         |
| PHC                     | 31 (50%) | 39.69 (12.20)   | 0.0020  |
| Hospital                | 31 (50%) | 49.45 (15.16)   |         |
| Health status (BMI) **  |       |                  |         |
| Min-max                 | 13.84–29.78 | 0.0439       |         |
| Median                  | 18.34                               |         |
| Average (SD)            | 19.11 (3.3)                        |         |
| Referred/not ***        |       |                  |         |
| Enrolled as a new patient | 33 (53%) | 43.53 (15.46)  | 0.1794  |
| Referred from another HC | 28 (45%) | 46.37 (13.36)  |         |
| Transportation mode ****|       |                  |         |
| Public transportation   | 16 (25.8%) | 45.96 (15.43)  | 0.0275  |
| Private car             | 7 (11.29%) | 59.11 (13.94)  |         |
| Motorcycle              | 38 (61.29%) | 41.49 (12.93)  |         |

Notes
* Mann Whitney
** Spearman
*** One-way ANOVA
**** Kruskal–Wallis
a SD = standard deviation.

https://doi.org/10.1371/journal.pone.0264912.t003
A model for the TB cascade in West Java from 2016 to 2024 was developed, based on our cost data and the PHO targets for the estimated number of TB cases. Assuming that Xpert MTB/RIF testing with four modules was used, the optimal capacity would be 2,880–3,000 tests per year (with routine calibration), according to 20–21 working days per month. Hence, in order to achieve 50% testing of the aggregate presumptive cases, a total of 108 machines in West Java was required in 2019. However, if the number of Xpert MTB/RIF tests was increased by 10% in 2024, 136 machines would be required. To detect all targeted cases in West Java using Xpert MTB/RIF testing for the 2019–2024 time period, as much as USD 56,353,833 will be required (see Table 7). Based on the National Strategic Plan, which stated that 75% of the tests will use Xpert MTB/RIF testing in 2024, West Java province should allocate an additional USD 1.8 million that year.

Finally, in terms of uncertainty, we assessed the range values around the mean using standard deviation, as presented in Supplementary Material 1. We calculated such values from the variations in the cities/districts (n = 27) in West Java. According to the findings, there were substantial variations between these areas that affected the mean values for the costs adjusted, suspected cases, and the total costs for TCM and SSM. Moreover, we presented the total costs (categorized by fiscal index) to specify the differences in the included parameters.

### Affordability at the province level

By tracking down the data, we found that the total health budget in West Java was USD 174,250,595 in 2017, while the budget for the TB program (excluding Xpert MTB/RIF testing)
### Table 5. Estimated costs for the TB diagnostic tests in Depok, 2019–2024.

| Type of Testing | 2019  | 2020  | 2021  | 2022  | 2023  | 2024  |
|-----------------|-------|-------|-------|-------|-------|-------|
| Type of test (SSM: Xpert MTB/RIF) | 60:40 | 50:50 | 48:52 | 45:55 | 42:58 | 40:60 |
| Number of cases |       |       |       |       |       |       |
| TB presumptive cases | 33,847 | 33,890 | 33,890 | 35,726 | 35,689 | 35,645 |
| TB cases estimated | 6,965  | 6,973  | 6,973  | 6,965  | 6,956  | 6,948  |
| Case detection target | 6,268  | 6,276  | 6,276  | 6,616  | 6,609  | 6,601  |
| Estimated number of cases tested |       |       |       |       |       |       |
| SSM | 20,308 | 16,945 | 16,267 | 16,077 | 19,649 | 20,700 |
| Xpert MTB/RIF | 13,539 | 34,229 | 32,859 | 32,476 | 30,278 | 28,801 |
| Total | 355,262 | 427,522 | 441,889 | 488,529 | 510,725 | 525,193 |
| Health system perspective cost (USD) |       |       |       |       |       |       |
| SSM | 41,022 | 34,229 | 32,859 | 32,476 | 30,278 | 28,801 |
| Xpert MTB/RIF | 314,240 | 409,030 | 476,924 | 523,483 | 561,692 | 588,217 |
| Total | 355,262 | 427,522 | 441,889 | 488,529 | 510,725 | 525,193 |
| Societal perspective cost (USD) |       |       |       |       |       |       |
| SSM | 59,909 | 49,988 | 47,988 | 47,427 | 44,218 | 42,061 |
| Xpert MTB/RIF | 470,616 | 682,999 | 719,532 | 743,412 | 785,473 | 730,426 |
| Total | 530,524 | 706,945 | 757,521 | 809,219 | 846,757 | 871,235 |
| Number of positive cases |       |       |       |       |       |       |
| SSM | 2,031  | 1,695  | 1,627  | 1,608  | 1,499  | 1,426  |
| Xpert MTB/RIF | 3,615  | 4,705  | 5,246  | 5,527  | 5,710  | 6,219  |
| Total | 5,646  | 6,219  | 6,332  | 6,854  | 7,026  | 7,136  |

Notes
* Useful life of Xpert MTB/RIF machine = 5 years
** Useful life of Xpert MTB/RIF machine = 10 years.

[https://doi.org/10.1371/journal.pone.0264912.t005](https://doi.org/10.1371/journal.pone.0264912.t005)

### Table 6. Funding for the TB program in Depok, 2017–2018.

| Component of Funding | 2017 USD | 2018 USD |
|----------------------|-----------|-----------|
| Funding for TB by component | % | % |
| Community involvement/education | 4,953 | 6.40 | 3,416 | 2.64 |
| Monitoring TB drug compliance | 50,763 | 65.65 | 62,447 | 48.44 |
| Outreach program | 8,220 | 10.63 | 10,816 | 8.39 |
| Cartridge ° | 13,390 | 17.32 | 52,250 | 40.53 |
| Total | 77,326 | 100 | 128,929 | 100 |
| Funding for all health programs by source | % | % |
| District budget || 23,175,801 | 81.20 | 25,276,235 | 79.41 |
| Province budget | 814,708 | 2.85 | 1,211,896 | 3.81 |
| Central budget °° °° | 1,366,992 | 4.79 | 1,435,720 | 4.51 |
| Donor support | 13,390 | 0.50 | 522,157 | 1.64 |
| Subsidies for the poor | 3,171,801 | 11.11 | 3,385,154 | 10.63 |
| Total | 28,542,692 | 100 | 31,831,162 | 100 |

Note
* Central level contribution
** Including transfer funds from the central level; °° In kind and direct subsidy.

[https://doi.org/10.1371/journal.pone.0264912.t006](https://doi.org/10.1371/journal.pone.0264912.t006)
| Category | Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|----------|------|------|------|------|------|------|------|
| Very high fiscal index (n = 12) | Presumptive TB cases | 422,275 | 422,777 | 422,777 | 445,738 | 445,230 | 444,685 |
| | Estimated TB cases | 86,890 | 86,992 | 86,992 | 86,890 | 86,785 | 86,682 |
| | Case finding target | 78,199 | 78,292 | 78,292 | 82,544 | 82,450 | 82,349 |
| | Number of cases using SSM | 211,137 | 211,388 | 219,844 | 245,156 | 258,233 | 266,811 |
| | Number of cases using Xpert MTB/RIF testing | 211,137 | 211,388 | 219,844 | 245,156 | 258,233 | 266,811 |
| | Total costs for SSM (USD) | 615,103 | 476,300 | 457,248 | 451,949 | 421,341 | 400,787 |
| | Total costs for Xpert MTB/RIF testing (USD) | 8,084,575 | 6,260,217 | 6,510,626 | 7,260,198 | 7,647,538 | 7,901,573 |
| | Average cost for Xpert MTB/RIF testing per district (USD) | 673,715 | 521,685 | 542,552 | 605,016 | 637,295 | 658,464 |
| High fiscal index (n = 9) | Presumptive TB cases | 152,010 | 152,194 | 152,194 | 155,050 | 160,261 | 160,072 |
| | Estimated TB cases | 31,277 | 31,314 | 31,314 | 31,277 | 31,240 | 31,205 |
| | Case finding target | 28,150 | 28,184 | 28,184 | 28,713 | 29,678 | 29,643 |
| | Number of cases using SSM | 76,005 | 76,097 | 79,141 | 85,278 | 92,951 | 96,043 |
| | Number of cases using Xpert MTB/RIF testing | 76,005 | 76,097 | 79,141 | 85,278 | 92,951 | 96,043 |
| | Total costs for SSM (USD) | 134,585 | 134,747 | 129,357 | 124,266 | 119,187 | 113,377 |
| | Total costs for Xpert MTB/RIF testing (USD) | 1,768,904 | 1,771,040 | 1,841,882 | 1,996,233 | 2,163,299 | 2,235,245 |
| | Average cost for Xpert MTB/RIF testing per district (USD) | 196,545 | 196,782 | 204,654 | 221,804 | 240,367 | 248,361 |
| Moderate fiscal index (n = 4) | Presumptive TB cases | 40,198 | 40,246 | 40,246 | 42,439 | 42,390 | 42,331 |
| | Estimated TB cases | 8,272 | 8,282 | 8,282 | 8,272 | 8,262 | 8,253 |
| | Case finding target | 6,488 | 7,453 | 7,453 | 7,859 | 7,850 | 7,839 |
| | Number of cases using SSM | 20,099 | 20,123 | 20,928 | 23,341 | 24,586 | 25,398 |
| | Number of cases using Xpert MTB/RIF testing | 20,099 | 20,123 | 20,928 | 23,341 | 24,586 | 25,398 |
| | Total costs for SSM (USD) | 39,158 | 39,205 | 37,637 | 37,207 | 34,687 | 32,988 |
| | Total costs for Xpert MTB/RIF testing (USD) | 514,675 | 515,293 | 535,904 | 597,707 | 629,593 | 650,373 |
| | Average cost for Xpert MTB/RIF testing per district (USD) | 128,669 | 128,823 | 133,976 | 149,427 | 157,398 | 162,593 |
| Low fiscal index (n = 2) | Presumptive TB cases | 7,128 | 7,139 | 7,139 | 7,528 | 7,517 | 7,511 |
| | Estimated TB cases | 1,467 | 1,469 | 1,469 | 1,467 | 1,465 | 1,464 |
| | Case finding target | 1,320 | 1,322 | 1,322 | 1,394 | 1,392 | 1,391 |
| | Number of cases using SSM | 3,564 | 3,569 | 3,427 | 3,587 | 3,157 | 3,005 |
| | Number of cases using Xpert MTB/RIF testing | 3,564 | 3,569 | 3,712 | 4,140 | 4,360 | 4,507 |
| | Total costs for SSM (USD) | 6,708 | 6,718 | 6,450 | 6,376 | 5,942 | 5,655 |
| | Total costs for Xpert MTB/RIF testing (USD) | 88,168 | 88,304 | 91,836 | 102,420 | 107,849 | 111,492 |
| | Average cost for Xpert MTB/RIF testing per district (USD) | 44,084 | 44,152 | 45,918 | 51,210 | 53,924 | 55,746 |
| West Java (n = 27) | Presumptive TB cases | 621,610 | 622,355 | 622,355 | 650,754 | 655,398 | 654,599 |
| | Estimated TB cases | 127,906 | 128,057 | 128,057 | 127,906 | 127,752 | 127,604 |
| | Case finding target | 115,113 | 115,251 | 115,251 | 120,510 | 121,370 | 121,222 |
| | Number of cases using SSM | 310,805 | 311,178 | 298,731 | 292,839 | 275,267 | 261,840 |
| | Number of cases using Xpert MTB/RIF testing | 310,805 | 311,178 | 323,625 | 357,915 | 380,131 | 392,759 |
| | Total costs for SSM (USD) | 652,691 | 653,473 | 627,334 | 614,963 | 578,061 | 549,863 |
| | Total costs for Xpert MTB/RIF testing (USD) | 8,435,250 | 8,445,363 | 8,783,177 | 9,713,805 | 10,316,751 | 10,659,487 |
| | Average cost for Xpert MTB/RIF testing per district (USD) | 312,417 | 312,791 | 325,303 | 359,771 | 382,102 | 394,796 |

https://doi.org/10.1371/journal.pone.0264912.t007
was USD 7,449,826 (see Table 8), of which 51.9% was supported by donors (mainly the Global Fund) [26, 27]. This indicated that the TB program activities were mainly relying on donor support.

Finally, the budget requisition for Xpert MTB/RIF testing in West Java in 2019 was USD 8,435,250 and it will increase to USD 10,316,751 in 2023, far exceeding its budget for the communicable disease programs (USD 606,200 in 2019 and USD 1,132,139 in 2023) [22]. However, with support from the MOH on laboratory infrastructure, and the budget for human resources and operational costs remaining under local government control, it seems unrealistic based on the evidence that only 4% of the health funds in West Java is dedicated toward the TB program (see Table 8).

### Discussion

Our study demonstrated that the cost of expanding the use of Xpert MTB/RIF testing for TB diagnosis is substantially larger, compared to the use of SSM alone or in combination with CXR. Interestingly, Xpert MTB/RIF testing not only imposed significant costs from the health system perspective, but also from the patients’ viewpoints, mainly because of the high cost of the machines, the patients’ costs (e.g., transportation and productivity loss) incurred, and the fact that only two sites provided this rapid test. Conforming to other studies, our findings showed that the rate of laboratory-confirmed TB diagnosis was considerably low, due to the poor quality of sputum, the troublesome path of diagnosis, and inaccurate reporting [28]. Meanwhile, SSM (the recommended test according to the Indonesian TB control guidelines) has a relatively lower sensitivity, while the gold standard mycobacterial culture test requires laboratory infrastructures that are not widely available in the country, with test results that return within four weeks. Conversely, rapid molecular tests, such as Xpert MTB/RIF testing, have a higher sensitivity (56%–74% vs. 88%) and specificity (91%–92% vs. 99%) [29, 30] than SSM, with a turnaround time as short as one day [31]. Hence, the use of Xpert MTB/RIF testing will increase diagnostic accuracy and eliminate any delays associated with the use of culture.

Furthermore, the use of Xpert MTB/RIF testing can give an additional yield of 16% for TB cases and 2% for cases of rifampicin-resistant TB, compared to using SSM alone. Assuming that each TB patient can infect up to 10 people within 18 months [30], using Xpert MTB/RIF testing can prevent as many as 16% of the new diagnosed cases. Consequently, the use of Xpert MTB/RIF testing could save economic losses [30]. Such testing can also reduce treatment costs, given the high cost of multi-drug-resistant tuberculosis or MDR-TB treatment [32].
However, testing all presumptive TB patients will significantly increase costs and be challenging, as asserted by the WHO [33]. Our study demonstrated that for West Java (a province with high TB prevalence), the cost of expanding the use of Xpert MTB/RIF testing would amount to USD 10,659,487 in 2024. Based on this statistic, Indonesia would face even higher budget requisitions to cover the targets for all 34 provinces.

In an effort to eliminate TB in Indonesia, which is predicted to be achieved by 2035, accelerated case detection with the help of Xpert MTB/RIF testing is expected to provide treatment for TB, MDR-TB, and TB-HIV cases. However, it needs operational improvement, including the recording and reporting of cases. In a related study of 44 health facilities in Indonesia, the examination of TB diagnosis using Xpert MTB/RIF testing produced a finding of 3.2% for DR-TB cases, which were followed up for further examination and treatment of MDR-TB [29]. Our study also revealed an increased number of cases following the introduction of Xpert MTB/RIF testing in 2017, after which the patients were referred to hospitals that provided MDR-TB treatment.

Under Indonesia’s decentralized system, the local government mostly finances the programmatic operational costs, while the provisions of supplies and infrastructure development are usually supported by the central government. In 2018, only 40% of the USD 294 million needed to finance the TB program in Indonesia was available, with the Global Fund providing close to 55% of the USD 35 million in international funding committed to Indonesia [34]. Considering the significant amount of support from the Global Fund and the heavy reliance on the central government for TB program financing, shifting the burden of financing Xpert MTB/RIF testing to the local government may not be feasible or acceptable. To put this in context, the city of Depok will need to reallocate USD 2,989,927 or roughly 23-fold of their health budget in 2018 to finance Xpert MTB/RIF expansion over the next four years.

The substantial increase in patient costs related to the use of Xpert MTB/RIF testing must also be considered. Typically, patient costs become a barrier that hinders the utilization of Xpert MTB/RIF testing in developing countries [5, 20], including Indonesia. Although patients enjoy free access to anti-TB drugs, they frequently incur high costs on travel and food and suffer from income losses [3, 35]. Similar studies in other countries have revealed that besides the direct cost of Xpert MTB/RIF testing, transportation remains an issue [29, 35]. In the West Java context, this should be considered as a component that requires subsidies from the government.

Given that the WHO stated that no patient should face catastrophic costs because of TB by 2020 as part of the End TB strategy [4], the study suggests that the formulation of a policy instrument is necessary to support patients with TB regarding high levels of household spending on TB diagnosis and treatment [19, 36]. Additionally, innovative efforts must be enhanced, such as public–private partnerships [9], which have been initiated in West Java. In this regard, engaging the private sector to refer TB suspects to services could lead to detecting other additional positive cases [37] and improving prevention services for latent TB infections [38–40]. Moreover, policy efforts should be in place to ensure demand creation from the patient perspective. Access to Xpert MTB/RIF diagnostic could be increased by involving private health care to provide the test.

Although the central government provides a subsidy of USD 54 per MDR-TB patient to support transportation for getting treatment, it is unclear how the subsidy will improve overall compliance [41]. Furthermore, the lack of follow-ups or no valid data on the number of successful treatments remains a major challenge. Given the resource constraints in a high-burden setting such as West Java, the NTP must create a mechanism on the number of Xpert MTB/RIF machines to be installed, and how to incorporate it into the current diagnostic algorithm. In this regard, the resources would be more efficiently utilized if a systematic plan based on
risk factors is developed using Xpert MTB/RIF testing, i.e., patients with previous TB treatment or contact with MDR-TB patients [42]. Meanwhile, since TB patients may live in areas where laboratory infrastructure is insufficient, the DHO must consider improving the network for patient access [33].

Since improving access to TB tests can lead to TB treatment, readiness on the supply side is required as well as an increase in patient compliance. However, the data revealed that the compliance and success rates in West Java are still below the target. Specifically, compliance to treatment decreased from 88.4% in 2016 to 73.9% in 2018, while the success rate of treatment for TB in 2016 remained low at 43% [27].

Finally, local commitment is essential for supporting operational costs, particularly for active case detection, active surveillance, information systems, and programs for ensuring compliance to TB treatment. In this regard, a systematic process of advocacy with the government at all levels is critical. However, unless all of the goals and strategic plans of the central government as well as the action plans at the sub-national level are ensured through political commitments, it is unrealistic for West Java to achieve TB elimination by the year 2030.

There are several limitations of this study that should be noted. First, the analysis of the data obtained from electronic TB registers at the local level might have produced underestimated information, given that the records were not fully maintained as expected. The target of presumptive cases was given by West Java PHO such that no epidemiological parameters based on primary data collection to support analysis, test repeat rates, and diagnostic accuracy may influence the result for budget impact. Second, the sub-national data was obtained from three districts, whereas the patient-level data was obtained from one region, even though the variation in West Java is wide. Ideally, the stratified random sampling approach is selected within the following strata: level of care, ownership (public or private), and diagnostic intervention available [43]. The current study captured data for health system costs from health centers and public hospitals only, while those for patient costs were collected from health centers and private hospitals. For a more detailed analysis, the sample size should be bigger. Third, this study did not cover HIV, pediatric, and TB MDR cases. Fourth, fiscal capacity in all districts in West Java is relatively similar; however, district readiness may be varied. Moreover, we were unable to obtain information on how local authorities consider the readiness of facilities. Finally, unless we perform a systematic tracking of TB funds in certain regions, the fragmented health budgeting system in Indonesia will continue to pose a challenge. Meanwhile, it will provide an opportunity for lessons to be learned in terms of understanding the commitment of the local government.

Conclusion

This study has added to the current limited knowledge on how Indonesia could develop a plan to increase TB case detection at the sub-national level. In order to accelerate the achievement of the case detection target up to 2024, West Java needs additional Xpert MTB/RIF machines and significant funds. Scaling up the TB tests also requires a commitment, based on careful consideration from both provider and patient perspectives. Moreover, support from the central government is necessary, with careful prioritization, since even one case detection can be quite costly. Finally, to gain support from the sub-national authorities, the NTP requires support from the Ministry of Internal Affairs, who can guide the local authorities to strongly support the MOH decree on TB diagnosis.

Supporting information

S1 Appendix. Informed consent and questionnaire. (PDF)
S1 Table. TB cases and fiscal index profile in West Java.
(PDF)

S2 Table. Estimated cases, case detection targets, and TB presumptive cases in West Java, 2019–2024.
(PDF)

S1 Fig. Graph of uncertainty analysis.
(PDF)

Acknowledgments
We would like to thank all of the patients who participated in this study in Depok municipality, both at the Puskesmas Pancoran Mas and Sentra Medika hospitals. We are also grateful to the team members and enumerators who were involved in this study, and Dr. Imran Pambudi from the NTP and Dr. Gita Parwati from the ICF project, who gave us the opportunity to explore initial costing. We would also like to thank the Depok DHO and the Sentra Medika hospital director and staff for providing all of the societal cost data. Finally, we are thankful for ibu Ina Susilawati from the Depok DHO, ibu Rukaya from Puskesmas Pancoran Mas, and the DHO officials for providing the data on the TB cases and health system costs.

Author Contributions
Conceptualization: Mardiati Nadjib, Retno Kusuma Dewi, Ery Setiawan.

Data curation: Mardiati Nadjib, Retno Kusuma Dewi, Ery Setiawan, Septiara Putri, Lusi Nursilawati Syamsi.

Formal analysis: Mardiati Nadjib, Retno Kusuma Dewi, Tri Yunis Miko, Panji Fortuna Hadisoemarto, Euis Ratna Sari.

Investigation: Mardiati Nadjib, Ery Setiawan, Septiara Putri, Euis Ratna Sari, Pujiyanto, Rani Martina, Lusi Nursilawati Syamsi.

Methodology: Mardiati Nadjib, Retno Kusuma Dewi.

Supervision: Mardiati Nadjib, Septiara Putri, Pujiyanto, Rani Martina, Lusi Nursilawati Syamsi.

Validation: Mardiati Nadjib, Retno Kusuma Dewi, Tri Yunis Miko, Panji Fortuna Hadisoemarto, Euis Ratna Sari.

Writing – original draft: Mardiati Nadjib, Retno Kusuma Dewi, Panji Fortuna Hadisoemarto.

Writing – review & editing: Mardiati Nadjib, Retno Kusuma Dewi, Ery Setiawan, Tri Yunis Miko, Septiara Putri, Panji Fortuna Hadisoemarto, Euis Ratna Sari, Pujiyanto, Rani Martina, Lusi Nursilawati Syamsi.

References
1. Institute for Health Metrics and Evaluation. DALY of Indonesia 1997 and 2017 [Internet]. University of Washington. 2018. Available from: https://vizhub.healthdata.org/gbd-compare/
2. WHO. Global Tuberculosis Report 2019. Geneva; 2019.
3. Collins D, Hafidz F, Mustikawati D. The economic burden of tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2017 Sep 1; 21(9):1041–8. https://doi.org/10.5588/ijtld.16.0896 PMID: 28826455
4. Ministry of Health RI. National Strategic Plan for Tuberculosis Control in Indonesia 2020–2024. 2020.
5. WHO. Global Tuberculosis Report 2016. World Health Organization. Geneva; 2016.
6. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. 2013 Sep; 42(3):708–20. https://doi.org/10.1183/09031936.00147912 PMID: 23258774
7. Muyoyeta M, Moyo M, Kasese N, Nhlovu M, Milimo D, Mwanza W, et al. Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings. Fox MP, editor. PLoS One. 2015 Jun 1; 10(6):1–18.
8. Ministry of Health RI. Ministry of Health Decree No 67 year 2016 about Management of Tuberculosis. Ministry of Law and Human Right RI Indonesia; 2017 p. 163.
9. Ministry of Health RI. Indonesian Public Private Mix Tuberculosis Control Action Plan: 2011–2014. Jakarta; 2014.
10. Khaparde S, Raizada N, Nair SA, Denkinger C, Sachdeva KS, Paramasivan CN, et al. Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis. Neyrolles O, editor. PLoS Med. 2011 Nov 8; 8(11):e1001120. https://doi.org/10.1371/journal.pmed.1001120 PMID: 22087078
11. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. Wilson D, editor. PLoS Med. 2011 Nov 8; 8(11):e1001120. https://doi.org/10.1371/journal.pmed.1001120 PMID: 22087078
12. Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, et al. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. Lancet Glob Heal. 2017 Jul; 5(7):e710–9. https://doi.org/10.1016/S2214-109X(17)30205-X PMID: 28619229
13. Philipsen RHHM Sánchez CI, Maduskar P, Melendez J, Peters-Bax L, Peter JG, et al. Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs. Sci Rep. 2015 Dec 27; 5(1):12215.
14. Naidoo P, Dunbar R, Du Toit E, Van Niekerk M, Squire SB, Beyers N, et al. Comparing Laboratory Costs of Smear/Culture and Xpert® MTB/RIF-based Tuberculosis Diagnostic Algorithms. Int J Tuberc Lung Dis. 2016. https://doi.org/10.5588/ijtld.16.0081 PMID: 27725051
15. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nijsten M, et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Value Heal. 2007 Sep; 10(5):336–47. https://doi.org/10.1111/j.1524-4733.2007.00187.x PMID: 17888098
16. Province Health Office of West Java. Resume Table of West Java Health Profile 2014. Bandung; 2014.
17. Center Bureau of Statistic. Purchasing Power Parity West Java and District Governments 2010–2017 [Internet]. Garut Center Bureau of Statistic. 2018 [cited 2019 May 14]. Available from: https://garutkab.bps.go.id/statitable/2018/05/14/368/pengeluaran-per-kapita-disesuaikan-ipm-metode-baru-provinsi-jawa-barat-dan-kabupaten-kota-tahun-2010—2017.html
18. CHEPS UI. Study Report: Economic evaluation component of the study: Tuberculosis Case Yield of Risk Group Screening Using Optimized Screening and Diagnosis Algorithm in Indonesia Primary Health Center. Jakarta; 2019. Forthcoming.
19. WHO. Protocol for Survey to Determine Direct and Indirect Costs Due to TB and to Estimate Proportion of TB-affected Households Experiencing Catastrophic Costs Due to TB. Geneva; 2015. 1–96 p.
20. Fuady A, Houweling TA, Mansyur M, Richardus JH. Adaptation of the Tool to Estimate Patient Costs Questionnaire into Indonesian Context for Tuberculosis-affected Households. Acta Med Indones. 2018 Jan; 50(1):3–10. PMID: 29686170
21. Ministry of Health RI. National Action Plan for TB Control through Strengthening TB Laboratories. Jakarta; 2016.
22. Provincial Development and Planning Board. District Medium-term Development Planning of West Java Province 2018–2023. Bandung; 2019.
23. FIND. GeneXpert®—FIND [Internet]. Find. 2020. Available from: https://www.finddx.org/pricing/genexpert/
24. CHEPS UI. District Health Account in Depok City 2017–2018. Depok; 2019.
25. Ministry of Finance RI. Ministry of Finance Decree No. 126 year 2019 about District Fiscal Capacity Mapping. 2019.
26. West Java Health Office. Health Profile in West Java Province 2017. West Java Health Office. Bandung; 2017.
27. Ministry of Health RI. Central and Regional Synergism in Realizing UHC through the Acceleration of Post-National Working Meeting 2018 Elimination of Tuberculosis. Jakarta; 2018.

28. National Institute of Health Research and Development. Evaluation of Case Detected Tuberculosis with Rapid Test Molecular in Indonesia 2018. Jakarta; 2019.

29. Pinto M, Steffen RE, Cobelens F, van den Hof S, Entringer A, Trajman A. Cost-effectiveness of the Xpert MTB/RIF assay for tuberculosis diagnosis in Brazil. Int J Tuberc Lung Dis. 2016 May 1; 20 (5):611–8. https://doi.org/10.5558/ijtld.15.0455 PMID: 27084814

30. WHO. Tuberculosis Fact Sheets [Internet]. World Health Organization. 2020 [cited 2019 Jan 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis

31. Kwak N, Choi SM, Lee J, Park YS, Lee C-HH, Lee S-MM, et al. Diagnostic Accuracy and Turnaround Time of the Xpert MTB/RIF Assay in Routine Clinical Practice. Wilkinson RJ, editor. PLoS One. 2013 Oct 29; 8(10):e77456. https://doi.org/10.1371/journal.pone.0077456 PMID: 24204834

32. Ryu YJ. Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms. Tuberc Respir Dis (Seoul). 2015; 78(2):64. https://doi.org/10.4046/trd.2015.78.2.64 PMID: 25861338

33. WHO. Xpert MTB/RIF assay for the diagnosis TB-Meeting report. World Health Organisation. Geneva; 2016.

34. StopTB Partnership. Tuberculosis (TB) situation in 2018 [Internet]. StopTB Partnership. 2019 [cited 2020 Jun 10]. Available from: http://www.tbindonesia.or.id/tag/tb-indonesia/

35. Mauch V, Woods N, Kirubi B, Kipruto H, Sitienei J, Klinkenberg E. Assessing access barriers to tuberculosis care with the Tool to Estimate Patients’ Costs: pilot results from two districts in Kenya. BMC Public Health. 2011 Dec 18; 11(1):43. https://doi.org/10.1186/1471-2458-11-43 PMID: 21244656

36. Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia’s implementation of universal health coverage. Infect Dis Poverty. 2018 Dec 12; 7(1):3. https://doi.org/10.1186/s40249-017-0382-3 PMID: 29325589

37. Mahendra Nath Y, Probando A, Ahmad RA, Utranin A, Trisnantoro L, Lindholm L, et al. The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogyakarta, Indonesia. Am J Trop Med Hyg. 2010 Jun 1; 82(6):1131–9. https://doi.org/10.4269/ajtmh.2010.09-0447 PMID: 20519613

38. Taninura T, Jaramillo E, Weil D, Raviglione M, Lonroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014 Jun 1; 43(6):1763–75. https://doi.org/10.1183/09031936.00193413 PMID: 24525439

39. Zerden D, Hafezi H, Potter J, Capone S, Matteelli A. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection. Int J Tuberc Lung Dis. 2017 Sep 1; 21 (9):965–76. https://doi.org/10.5558/ijtld.16.0935 PMID: 28826445

40. Suen S-C, Bendavid E, Goldhaber-Fiebert JD. Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India. Int J Tuberc Lung Dis. 2015 Sep 1; 19(9):1115–24. https://doi.org/10.5558/ijtld.15.0158 PMID: 26260835

41. Ministry of Health RI. Submission of Global Fund Payments in Integrated Management of Drug-Resistant TB Control. Jakarta; 2018.

42. Kirwan DE, Cárdenas, María Kathia, Gilman RH. Rapid Implementation of New TB Diagnostic Tests: Is It Too Soon for a Global Roll-Out of Xpert MTB/RIF? Am J Trop Med Hyg. 2012 Aug 1; 87(2):197–201. https://doi.org/10.4269/ajtmh.2012.12-0107 PMID: 22855746

43. Cunnamo L, Garcia Baena I, Gomez G, Laurence Y, Levin C, Siapka M, et al. Costing guidelines for tuberculosis interventions [Internet]. Geneva: World Health Organization; 2019. Available from: https://www.who.int/tb/publications/costing_guidelines/en/